Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 95,730,208
  • Shares Outstanding, K 2,035,081
  • Annual Sales, $ 48,300 M
  • Annual Income, $ -8,948 M
  • EBIT $ 13,452 M
  • EBITDA $ 23,052 M
  • 60-Month Beta 0.36
  • Price/Sales 1.96
  • Price/Cash Flow 7.90
  • Price/Book 5.42

Options Overview Details

View History
  • Implied Volatility 31.38% ( -2.73%)
  • Historical Volatility 19.99%
  • IV Percentile 75%
  • IV Rank 32.42%
  • IV High 55.70% on 04/10/25
  • IV Low 19.71% on 12/26/24
  • Put/Call Vol Ratio 1.09
  • Today's Volume 16,013
  • Volume Avg (30-Day) 28,171
  • Put/Call OI Ratio 0.97
  • Today's Open Interest 593,825
  • Open Int (30-Day) 592,743

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 1.53
  • Number of Estimates 9
  • High Estimate 1.73
  • Low Estimate 1.05
  • Prior Year 2.07
  • Growth Rate Est. (year over year) -26.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.17 +3.24%
on 06/30/25
50.76 -6.11%
on 06/11/25
-1.34 (-2.73%)
since 06/09/25
3-Month
44.00 +8.32%
on 05/14/25
53.42 -10.78%
on 04/10/25
-6.08 (-11.31%)
since 04/09/25
52-Week
39.92 +19.37%
on 07/15/24
63.33 -24.74%
on 03/11/25
+6.80 (+16.64%)
since 07/09/24

Most Recent Stories

More News
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?

Bristol Myers’ BMY growth portfolio primarily comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others.Among these, immuno-oncology drug Opdivo...

MRK : 83.71 (+2.88%)
RHHBY : 40.8700 (+1.95%)
BMY : 47.66 (+1.32%)
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6...

AZN : 70.82 (+1.14%)
MRK : 83.71 (+2.88%)
PFE : 25.56 (-0.23%)
BMY : 47.66 (+1.32%)
Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?

Exelixis EXEL has put up a stellar performance so far this year. Shares of the biotech company have rallied 35.2% in the past three months compared with the industry’s growth of 11.8%. The stock has...

MRK : 83.71 (+2.88%)
EXEL : 44.07 (+1.29%)
BMY : 47.66 (+1.32%)
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca

Shares of clinical-stage company Summit Therapeutics SMMT rose nearly 9% on Thursday following a report issued by Bloomberg, which stated that pharma giant AstraZeneca AZN is in discussions with the company...

AZN : 70.82 (+1.14%)
MRK : 83.71 (+2.88%)
SMMT : 24.74 (+7.61%)
BMY : 47.66 (+1.32%)
Warren Buffett Owns 9 Ultra-High-Yield Dividend Stocks. Here's the Best of the Bunch.

FYBR : 36.57 (unch)
VZ : 42.61 (-1.05%)
CVX : 153.02 (-0.14%)
KHC : 26.45 (+0.08%)
BRK.TO : 35.66 (+0.37%)
SIRI : 24.27 (-0.70%)
PFE : 25.56 (-0.23%)
O : 56.92 (-0.99%)
BMY : 47.66 (+1.32%)
ARCC : 22.52 (+0.45%)
CPB : 30.74 (-0.97%)
LAMR : 124.48 (+0.73%)
Will The Decline in Legacy Drugs Pull Down BMY's Top Line?

Bristol Myers’ BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane.Revenues for the Legacy Portfolio plunged 20% in the first quarter to $5.64 billion due to the continued...

MRK : 83.71 (+2.88%)
PFE : 25.56 (-0.23%)
BMY : 47.66 (+1.32%)
AI Isn’t Just About Nvidia: 2 Rising Stars in the Artificial Intelligence Race

These two stocks are unseen giants powering the future.

NVDA : 162.88 (+1.80%)
AAPL : 211.14 (+0.54%)
QCOM : 159.35 (-0.06%)
$SPX : 6,263.26 (+0.61%)
XOM : 113.80 (-0.34%)
ERIC : 8.19 (-4.10%)
AMD : 138.41 (+0.43%)
AI : 27.39 (+3.87%)
BKR : 39.33 (-1.94%)
AMZN : 222.54 (+1.45%)
TSM : 231.84 (+1.75%)
BMY : 47.66 (+1.32%)
Is Pfizer Stock a Yield Trap?

BBIO : 45.98 (+6.46%)
NVS : 122.94 (+1.04%)
PFE : 25.56 (-0.23%)
BMY : 47.66 (+1.32%)
Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth

Pfizer PFE has committed significant resources for the development of treatments in the fields of oncology, internal medicine, immunology, inflammation and vaccines.Over the past decade, Pfizer has strengthened...

AZN : 70.82 (+1.14%)
MRK : 83.71 (+2.88%)
PFE : 25.56 (-0.23%)
BMY : 47.66 (+1.32%)
Are Options Traders Betting on a Big Move in Bristol-Myers Squibb Stock?

Investors in Bristol-Myers Squibb Company BMY need to pay close attention to the stock based on moves in the options market lately. That is because the July 18, 2025 $25 Call had some of the highest implied...

BMY : 47.66 (+1.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 48.61
2nd Resistance Point 48.19
1st Resistance Point 47.93
Last Price 47.66
1st Support Level 47.25
2nd Support Level 46.83
3rd Support Level 46.57

See More

52-Week High 63.33
Fibonacci 61.8% 54.39
Fibonacci 50% 51.63
Fibonacci 38.2% 48.87
Last Price 47.66
52-Week Low 39.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar